Q73398648 Dotaz Zobrazit nápovědu
Jessenius
215 stran : ilustrace (převážně barevné) ; 24 cm
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- traumatologie
- endokrinologie
- NLK Publikační typ
- kolektivní monografie
MicroRNA jsou krátké (18-24 nukleotidů) nekódující, velmi stabilní molekuly RNA, jejichž funkce zahrnuje vše od regulace klíčových signálních drah na molekulární úrovni až po rychlou buněčnou odpověď organismu na patologické stavy. microRNA jsou stabilní v tělních tekutinách a představují velmi perspektivní diagnostický cíl pro včasnou identifikaci široké škály onemocnění. V tomto souhrnném článku je uveden přehled kandidátních diagnostických miRNA vhodných pro využití v diagnostice onkologické kardiotoxicity.
MicroRNAs are very stable short (18-24) noncoding RNAs. The function of miRNA molecules includes everything from the regulation of key signalling pathways at the molecular level to the rapid cellular response to pathological conditions. miRNAs are stable in body fluids and represent a very promising diagnostic targets for the early identification of a wide range of diseases. This summary article provides an overview of candidate diagnostic miRNAs suitable for use in the diagnosis of oncological cardiotoxicity.
- MeSH
- biochemie * MeSH
- klinické laboratorní techniky MeSH
- kongresy jako téma MeSH
- Publikační typ
- zprávy MeSH
A number of microRNAs are involved in the pathophysiological events associated with heart disease. In this review, we discuss miR-21, miR-1, miR-23a, miR-142-5p, miR-126, miR-29, miR-195, and miR-499 because they are most often mentioned as important specific indicators of myocardial hypertrophy and fibrosis leading to heart failure. The clinical use of microRNAs as biomarkers and for therapeutic interventions in cardiovascular diseases appears highly promising. However, there remain many unresolved details regarding their specific actions in distinct pathological phenomena. The introduction of microRNAs into routine practice, as part of the cardiovascular examination panel, will require additional clinically relevant and reliable data. Thus, there remains a need for additional research in this area, as well as the optimization and standardization of laboratory procedures which could significantly shorten the determination time, and make microRNA analysis simpler and more affordable. In this review, we aim to summarize the current knowledge about selected microRNAs related to heart failure, including their potential use in diagnosis, prognosis, and treatment, and options for their laboratory determination.
- Publikační typ
- abstrakt z konference MeSH
BACKGROUND: The Endoscopic sleeve gastroplasty (ESG) is one of the new advanced restrictive techniques of bariatric endoscopy. The principle of this bariatric technique is the reduction of stomach volume through endoscopic plication. The long-term efficacy and metabolic effects of this procedure are the subject of this study. METHODS: 20 patients were enrolled; four men, sixteen women. Then they were followed for 24 months in terms of glycemic control, body composition, vitamin, and nutritional status. Observed parameters included glucose, triacylglycerols, high- and low-density lipoprotein cholesterol, micro and macro nutrients, fat mass, and lean body mass. RESULTS: We observed significant weight loss and a decrease body composition resulted from procedure vs. baseline, with levels of blood glucose also showing statistically significant reductions. The most notable decline in measured values was observed in period six months after the procedure. No significant changes were observed in measurement of micronutrients. CONCLUSIONS: Good restriction results were obtained following ESG, which might be mediated via altered glucose metabolism. The ESG method has shown a positive effect on fat and muscle mass. Unlike surgical methods, there were no deficits or deficiencies, especially in terms of essential vitamin levels.
- MeSH
- gastroplastika * MeSH
- hmotnostní úbytek MeSH
- lidé MeSH
- morbidní obezita * chirurgie MeSH
- vitaminy MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Cíle: Cílem této studie bylo ověření RT-LAMP testů za účelem nahrazení RT PCR testů pro diagnostiku SARS-CoV-2. Typ studie: Metodická studie. Název a sídlo pracoviště: Ústav laboratorní medicíny, Oddělení klinické biochemie, Fakultní nemocnice Ostrava. Metody: Studie zahrnovala 1018 vzorků anonymizovaných pacientů. Izolace virové RNA byla provedena za použití izolačního kitu Automated RNA Isolation Kit na pipetovací stanici Bravo firmy Agilent. Vyizolované vzorky RNA byly použity k detekci viru SARS-CoV-2 pomocí metody RT-PCR za použití diagnostické soupravy COVID-19 Multiplex RT-PCR a metody RT-LAMP pomocí diagnostické soupravy AUMED RT-LAMP Assay SARS-CoV- 2. Výsledky: Metodou RT-PCR bylo detekováno 32.1 % pozitivních vzorků a 67.9 % negativních vzorků. Vedle toho metodou RT-LAMP bylo detekováno 27.9 % pozitivních vzorků a 72.1 % negativních vzorků. Ze 327 pozitivních vzorků identifikovaných pomocí RT-PCR bylo metodou RT-LAMP identifikováno pouze 247 vzorků, 80 vzorků bylo falešně negativních. Z toho vyplývá, že rozdíl mezi metodami je 11.6 %. Test RT-LAMP vykazuje 94.5% specificitu a 75.5% senzitivitu. Obě testované metody vykazují velmi dobrou shodu (k = 0,725) Závěr: Testovaná metoda RT-LAMP, na rozdíl od RT-PCR, není za současných podmínek vhodná pro stanovení SARSCoV-2
Objectives: The aim of this study was to verify whether the RT-LAMP assay for SARS-CoV-2 determination can replace the RT-PCR assay. Design: Methodological study. Settings: Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava. Material and methods: The study included 1018 samples of anonymized patients. Viral RNA isolation was performed using the Automated RNA Isolation Kit using an Agilent Bravo pipetting station. The isolated RNA samples were used to detect the virus by RT-PCR using the COVID-19 Multiplex RT-PCR Kit and reverse transcription and loop-mediated isothermal amplification (RT LAMP) using the AUMED test RT-LAMP Assay SARS-CoV-2. Results: 32.1 % of positive samples and 67.9 % of negative samples were detected by the RT-PCR method. In addition, 27.9 % of positive samples and 72.1 % of negative samples were detected by RT-LAMP method. Of the 327 positive samples identified by RT PCR, 247 samples were true positive, but 80 samples were false negative. It follows that the discrepancy of both tested methods was found to be 11.6 %. The RT-LAMP assay showed 94.50% specificity and 75.54% sensitivity. There was a substantial agreement between the two testing methods (k = 0.725). Conclusions: The tested RT-LAMP method, unlike RT-PCR, is not suitable for SARS-CoV-2 determination under current conditions.
BACKGROUND: The evaluation of the predictive value of the neutrophil gelatinase-associated lipocalin (NGAL) for an early acute kidney injury (AKI) development in severely injured patients. Determination of the time-dependent roles of trauma-related physiologic markers of tissue hypoxia, systemic inflammation and rhabdomyolysis in AKI development. METHODS: 81 adult patients were screened for the presence of AKI for eight consecutive days following the injury. Arterial levels of plasma NGAL, lactate, interleukin-6, procalcitonin, and myoglobin were investigated at 24 hours (T1), 48 hours (T2), and 96 hours (T3) after the injury. RESULTS: The incidence of AKI was 32.1 %. Patients with AKI were older, but no significant difference in injury severity was observed. NGAL levels were significantly higher in the AKI group at T1, T2, and T3 when compared to the non-AKI group. Lactate levels were significantly higher in the AKI group at T2 only, and IL-6 levels were significantly higher in the AKI group at T2 and T3. Procalcitonin and myoglobin levels were significantly higher in the AKI group at T1, T2, and T3, when compared to the non-AKI group. Positive correlations were found between plasma NGAL and all screened physiological factors at all defined time points. CONCLUSION: Development of AKI after blunt trauma is very complex and multifactorial. Activation of the systemic inflammatory response and rhabdomyolysis (high concentration of myoglobin) were strongly involved in AKI development. Blood NGAL levels after injury were significantly higher in patients, who developed posttraumatic AKI. Plasma NGAL, lactate, procalcitonin, interleukin-6, and myoglobin had potential to be useful parameters for risk stratification and prediction of AKI after trauma (Tab. 6, Ref. 40).
- MeSH
- akutní poškození ledvin * epidemiologie etiologie krev prevence a kontrola MeSH
- dospělí MeSH
- hypoxie etiologie komplikace MeSH
- lidé MeSH
- lipokalin-2 krev MeSH
- rány a poranění * komplikace krev MeSH
- rhabdomyolýza etiologie komplikace MeSH
- rizikové faktory MeSH
- statistika jako téma MeSH
- zánět etiologie komplikace MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- klinická studie MeSH
- práce podpořená grantem MeSH
Publikace je společným stanoviskem České společnosti klinické biochemie a Společnosti pro metabolická onemocnění skeletu k využití markerů kostního obratu u pacientů s osteoporózou. Je doporučeno užívat PINP v μg/L jako marker kostní novotvorby a CTX-I v ng/L jako marker kostní resorpce. Odběr vzorku krve se provádí po nočním lačnění a je třeba se vyhnout enormní fyzické zátěži 24h před odběrem, u PINP není lačnění třeba. Vzorky krve odebírejte vždy mezi 7:00 -10:00 dopoledne. Akceptovatelné jsou jak sérum, tak EDTA plazma. EDTA plazma je vhodnější, když není možné CTX-I zpracovat do 8 hodin. Optimální doba separace krvinek od plazmy či séra je do dvou hodin po odběru. PINP není vhodným parametrem při léčbě systémově podávanými kortikoidy, kromě sledování efektu anabolické terapie. Abychom sjednotili interpretaci CTX-I a PINP, je doporučeno užívat pro systémy firmy Roche: základní referenční mez (CTX-I 100-600 ng/L u žen, 70-700 ng/L u mužů), (PINP 20 – 70 μg/L u žen i mužů), horní patologická mez (CTX-I 1000 ng/L u žen, 850 ng/L u mužů), (PINP 100 μg/L u mužů i žen) a pro firmu IDS: základní referenční mez ( CTX-I 50-670 ng/L u žen, 90-780 ng/L u mužů), (PINP 20 – 75 μg/L u žen, 20-80 μg/L u mužů), horní patologická mez (CTX-I 1050 ng/L u žen, 850 ng/L u mužů), (PINP 100 μg/L u mužů i žen). Pro monitorování terapie je definována změna sérových hodnot CTX-I a PINP o 25 % jako LSC (nejmenší signifikantní změna), nebo v absolutní hodnotě to znamená změnu sérových hodnot CTX-I o 100 ng/L a u PINP o 10 μg/L.
The publication is a joint position of the Czech Society of Clinical Biochemistry and the Society for Metabolic Skeletal Diseases on the use of bone turnover markers in patients with osteoporosis. It is recommended to use PINP in μg/L as a marker of bone formation and CTX-I in ng/L as a marker of bone resorption. Blood sampling should be performed after an overnight fasting, an enormous physical load 24 hours prior to collection should be also avoided. Always take blood samples between 7:00 and 10:00 in the morning. Both serum and EDTA plasma are acceptable. EDTA plasma is preferable when CTX-I cannot be processed within 8 hours. PINP is not an optimal parameter in patients monitoring treated by corticoids, except anabolic therapy monitoring. Harmonised reference limits were recommended to unify their interpretation. For Roche systems we suggested basal reference range (CTX-I 100-600 ng/L for women, 70-700 ng/L for men), (PINP 20-70 μg/L for both men and women) ), upper pathological limit (CTX-I 1000 ng/L for women, 850 ng/L for men), (PINP 100 μg/L for both men and women) For IDS systems we suggested to use basal reference limit (CTX-I 50-670 ng/L in women, 90-780 ng/L in men), (PINP 20-75 μg/L in women, 20-80 μg/L in men), upper pathological limit (CTX-I 1050 ng/L in women, 850 ng/L in men), (PINP 100 μg/L in both men and women). For therapy monitoring, a 25% change in serum CTX-I and PINP values is defined as LSC (least significant change), or in absolute values it means 100 ng/L change of serum CTX-I and 10 μg/L change for PINP.
- Klíčová slova
- kostní markery, PINP, CTX-I,
- MeSH
- biologické markery krev MeSH
- lidé MeSH
- osteoporóza * diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH